Document Detail

Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease.
MedLine Citation:
PMID:  18799820     Owner:  NLM     Status:  MEDLINE    
Angiotensin-converting enzyme inhibitors proved to be effective in the primary and secondary prevention of cardiovascular diseases. Clinical effectiveness of this group of agents may largely depend on their pleiotropic effects. The purpose of this study was to compare the effects of plasma- and tissue-type angiotensin-converting enzyme inhibitors on blood pressure and on systemic inflammation, hemostasis and oxidative functions in normotensive patients with stable coronary artery disease. Ninety patients with stable coronary artery disease enrolled into the study were randomly divided into three different groups, simultaneously treated with enalapril (20 mg/d, n = 30), perindopril (4 mg/d, n = 30) or placebo (n = 30). Plasma lipid profile and the levels of oxidized low density lipoproteins (LDLs), monocyte chemoattractant protein (MCP)-1, interleukin-10, C-reactive protein (CRP), fibrinogen and plasminogen activator inhibitor (PAI)-1 were determined at the beginning of the study and after 30 and 90 days of treatment. Seventy-six patients completed the trial. Neither enalapril nor perindopril affected blood pressure or plasma lipids. Perindopril significantly reduced plasma levels of oxidized LDLs, CRP, MCP-1, fibrinogen and PAI-1, and increased interleukin-10. The effect of enalapril on these markers of systemic inflammation, hemostasis and oxidative functions was much less pronounced. The results showed that enalapril and perindopril were devoid of a blood pressure-lowering effect in normotensive patients with stable coronary artery disease. Perindopril was superior to enalapril in exhibiting antioxidant, antithrombotic and profibrinolytic activities. The treatment-induced changes in the balance between pro- and antiinflammatory cytokines and in hemostasis may contribute to the clinical effectiveness of tissue angiotensin-converting enzyme inhibitors in the therapy of atherosclerosis-related disorders.
Robert Krysiak; Bogusław Okopień
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacological reports : PR     Volume:  60     ISSN:  1734-1140     ISO Abbreviation:  Pharmacol Rep     Publication Date:    2008 Jul-Aug
Date Detail:
Created Date:  2008-09-18     Completed Date:  2009-01-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101234999     Medline TA:  Pharmacol Rep     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  514-23     Citation Subset:  IM    
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Blood Glucose / drug effects
Blood Pressure / drug effects*
Cholesterol / blood
Coronary Disease / blood,  drug therapy*
Double-Blind Method
Enalapril / adverse effects,  therapeutic use*
Hemostasis / drug effects
Middle Aged
Perindopril / therapeutic use*
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Blood Glucose; 57-88-5/Cholesterol; 75847-73-3/Enalapril; 82834-16-0/Perindopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Taurine modulates calcium influx under normal and ototoxic conditions in isolated cochlear spiral ga...
Next Document:  CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloprotei...